Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

Sezer, A.2022-08-032022-08-0320211556-0864http://hdl.handle.net/11727/7216enginfo:eu-repo/semantics/closedAccessRandomised Controlled TrialsPhase II and III Clinical TrialsImmune checkpoint inhibitorsClinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1Conference Object1610S951S951000709606500217